IL160928A0 - Use of histamine to treat liver disease - Google Patents

Use of histamine to treat liver disease

Info

Publication number
IL160928A0
IL160928A0 IL16092802A IL16092802A IL160928A0 IL 160928 A0 IL160928 A0 IL 160928A0 IL 16092802 A IL16092802 A IL 16092802A IL 16092802 A IL16092802 A IL 16092802A IL 160928 A0 IL160928 A0 IL 160928A0
Authority
IL
Israel
Prior art keywords
histamine
liver disease
treat liver
treat
disease
Prior art date
Application number
IL16092802A
Other languages
English (en)
Original Assignee
Maxim Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxim Pharm Inc filed Critical Maxim Pharm Inc
Publication of IL160928A0 publication Critical patent/IL160928A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
IL16092802A 2001-10-19 2002-10-11 Use of histamine to treat liver disease IL160928A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34362801P 2001-10-19 2001-10-19
US34001101P 2001-10-30 2001-10-30
PCT/US2002/032675 WO2003035095A1 (en) 2001-10-19 2002-10-11 Use of histamine to treat liver disease

Publications (1)

Publication Number Publication Date
IL160928A0 true IL160928A0 (en) 2004-08-31

Family

ID=26991924

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16092802A IL160928A0 (en) 2001-10-19 2002-10-11 Use of histamine to treat liver disease

Country Status (8)

Country Link
US (1) US20030091553A1 (xx)
EP (1) EP1435984A1 (xx)
JP (1) JP2005510501A (xx)
KR (1) KR20040058192A (xx)
CN (1) CN1571674A (xx)
CA (1) CA2461661A1 (xx)
IL (1) IL160928A0 (xx)
WO (1) WO2003035095A1 (xx)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092062A1 (en) * 2001-10-24 2003-05-15 Reddy M. Parameswara Immobilizing biological molecules
US7129049B2 (en) * 2003-12-22 2006-10-31 Regents Of The University Of Minnesota Method of detecting equine glycogen storage disease IV
US7378112B2 (en) * 2005-11-28 2008-05-27 Sahajanand Biotech Pvt. Ltd. Herbal composition to improve psychological functions as an anxiolytic, tranquilizer, and non-narcotic sedative, as well as other physiological functions
JP5004529B2 (ja) * 2006-08-04 2012-08-22 株式会社日清製粉グループ本社 ヒスタミン遊離抑制剤
JP2009046465A (ja) * 2007-07-23 2009-03-05 Maruzen Pharmaceut Co Ltd 皮膚化粧料及び飲食品
MX2011010956A (es) * 2009-04-17 2012-01-27 Colby Pharmaceutical Company Composiciones farmaceuticamente activas que comprenden moduladores de estres oxidativo (osm por sus siglas en inglés), nuevas entidades quimicas, composiciones y usos.
US10052299B2 (en) 2009-10-30 2018-08-21 Retrotope, Inc. Alleviating oxidative stress disorders with PUFA derivatives
JP6145087B2 (ja) 2011-04-26 2017-06-07 レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． Ｐｕｆａ酸化関与障害
EP2701696B1 (en) 2011-04-26 2020-06-03 Retrotope, Inc. Impaired energy processing disorders and mitochondrial deficiency
US10154983B2 (en) 2011-04-26 2018-12-18 Retrotope, Inc. Neurodegenerative disorders and muscle diseases implicating PUFAs
KR102110200B1 (ko) 2011-04-26 2020-05-13 레트로토프 인코포레이티드 산화성 망막 질환
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
CN102940634A (zh) * 2012-11-05 2013-02-27 海南卫康制药(潜山)有限公司 异烟肼茴三硫组合物及其口服制剂制剂
EP2999499B1 (en) * 2013-05-22 2019-07-17 Zensun (Shanghai) Science & Technology, Co., Ltd. Extended release of neuregulin for treating heart failure
CN104623428A (zh) * 2015-03-13 2015-05-20 庄彩梅 一种缓解遗传性酪氨酸血症的中药制剂及其制备方法
KR102643910B1 (ko) 2015-11-23 2024-03-06 레트로토프 인코포레이티드 1,4-다이엔 시스템에 대한 부위 특이적인 동위원소 표지법
CN107823635A (zh) * 2017-11-29 2018-03-23 杭州睿道医药科技有限公司 锰型高稳定性超氧化物歧化酶的应用
AU2021224854A1 (en) 2020-02-21 2022-10-06 Biojiva Llc Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4336168A (en) * 1980-04-28 1982-06-22 Tenneco Chemicals, Inc. Stable liquid antimony stabilizer compositions and vinyl halide resins containing same
US4573996A (en) * 1984-01-03 1986-03-04 Jonergin, Inc. Device for the administration of an active agent to the skin or mucosa
US4597961A (en) * 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
US4596807A (en) * 1985-03-26 1986-06-24 Serotonin Industries Of Charleston Method and compositions for controlling pain, depression and sedation
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US5122127A (en) * 1985-05-01 1992-06-16 University Of Utah Apparatus and methods for use in administering medicaments by direct medicament contact to mucosal tissues
US5312325A (en) * 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
US4839174A (en) * 1987-10-05 1989-06-13 Pharmetrix Corporation Novel transdermal nicotine patch
US4943435A (en) * 1987-10-05 1990-07-24 Pharmetrix Corporation Prolonged activity nicotine patch
US4908213A (en) * 1989-02-21 1990-03-13 Schering Corporation Transdermal delivery of nicotine
DE69033848T2 (de) * 1989-07-21 2002-04-04 Suntory Ltd Osaka Mittel zur Verbesserung der Leberfunktion
US5679337A (en) * 1991-06-14 1997-10-21 Professional Pharmaceutical, Inc. Method and composition for topical treatment of Aphthous stomatitis histamine using phosphate as active ingredient
DE69231536T2 (de) * 1991-08-26 2001-06-13 Abbott Lab Verbindungen und methoden zur sublingualen oder buccalen verabreichung von therapeutischen agentien
CA2075517C (en) * 1992-04-01 1997-03-11 John Wick Transdermal patch incorporating a polymer film incorporated with an active agent
SE513429C2 (sv) * 1992-06-03 2000-09-11 Syntello Inc Preparat för aktivering av naturliga mördarceller, vilket preparat innehåller interferon alfa och biogena aminer
US5637315A (en) * 1993-01-04 1997-06-10 Thomas Jefferson University Treatment of disease states induced by oxidative stress
US5474527A (en) * 1993-03-29 1995-12-12 Bettinger; David S. Positive displacement transdermal system
US5549906A (en) * 1993-07-26 1996-08-27 Pharmacia Ab Nicotine lozenge and therapeutic method for smoking cessation
MX9605717A (es) * 1994-05-18 1998-05-31 Inhale Therapeutic Syst Metodos y composiciones para la formulacion de polvo seco de interferones.
FI95441C (fi) * 1994-05-31 1996-02-12 Leiras Oy Inhalointilaitteen lääkeainekammio
US5804203A (en) * 1994-12-21 1998-09-08 Cosmederm Technologies Topical product formulations containing strontium for reducing skin irritation
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US6155266A (en) * 1995-05-08 2000-12-05 Maxim Pharmaceuticals, Inc. Method for treatment of cancer and infectious disease
DK0865302T3 (da) * 1995-12-07 2000-10-02 Jago Pharma Ag Inhalator til gentagen dosisvis afgivelse af farmakologisk tørpulver
US6071942A (en) * 1996-05-14 2000-06-06 Maxim Pharmaceuticals, Inc. Elevation of circulating blood histamine levels
US5871010A (en) * 1996-06-10 1999-02-16 Sarnoff Corporation Inhaler apparatus with modified surfaces for enhanced release of dry powders
DE19710631B4 (de) * 1997-03-14 2006-02-09 Zf Sachs Ag Schnellverschluß zur Montage eines Druckmittelzylinders an einem Gehäuse
SE9702086D0 (sv) * 1997-06-02 1997-06-02 Biophausia Ab Anti-cancer drug delivery to solid tumors
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage

Also Published As

Publication number Publication date
JP2005510501A (ja) 2005-04-21
CN1571674A (zh) 2005-01-26
WO2003035095A1 (en) 2003-05-01
KR20040058192A (ko) 2004-07-03
CA2461661A1 (en) 2003-05-01
US20030091553A1 (en) 2003-05-15
EP1435984A1 (en) 2004-07-14

Similar Documents

Publication Publication Date Title
IL160928A0 (en) Use of histamine to treat liver disease
IL162533A0 (en) Chalcone derivatives and their use to treat diseases
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
AU2003239568A1 (en) Pyrrolotriazinone compounds and their use to treat diseases
IL160884A0 (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
GB2393202B (en) Methods of well treatment
GB0103973D0 (en) Improvements relating to skin prickers
IS6891A (is) Aðferðir við gjöf epóþílon hliðstæðna við meðferðkrabbameins
HRP20030874A2 (en) Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
PL373759A1 (en) Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases
GB0103977D0 (en) Improvements relating to skin prickers
GB0320238D0 (en) Treatment of disease
GB0023915D0 (en) Treatment of neuroinflammatory disease
AU2002364964A8 (en) Galliumcomplexes of 3-hydroxy-4-pyrones to treat mycobacterial infections
MXPA03007653A (es) Uso de lp82 para tratar trastornos hematopoyeticos.
AU2002351374A8 (en) Antibodies to treat cancer
HRP20020729A2 (en) Treatment of psoriasis
EP1411985A4 (en) TREATMENT OF PARASITICAL DISEASES
PL369402A1 (en) Use for the treatment of gastroesophageal reflux disease
HUP0402298A3 (en) Use of desoxypeganine for treating clinical depression
GB0101146D0 (en) Treatment of skin conditions
IL164099A0 (en) Use of interleukin-19 to treat cervical cancer
GB0100092D0 (en) Treatment of degenerative diseases
HUP0400007A2 (hu) Alkanoil-L-karnitin alkalmazása anhedónia kezelésére szolgáló gyógyászati készítmény előállítására
GB0120784D0 (en) The treatment of liver disease